Suppliers and packagers for BELRAPZO

BELRAPZO

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Eagle Pharms	BELRAPZO	bendamustine hydrochloride	SOLUTION;INTRAVENOUS	205580	NDA	Eagle Pharmaceuticals, Inc	42367-521-25	1 VIAL, MULTI-DOSE in 1 CARTON (42367-521-25) / 4 mL in 1 VIAL, MULTI-DOSE	2019-06-03

Last updated: July 29, 2025

ppliers for the Pharmaceutical Drug: Belrapzo

Introduction

Belrapzo, marketed primarily for the treatment of infectious diseases such as Clostridium difficile infections, is a pharmaceutical product whose commercial success hinges on its supply chain robustness. With the increasing global demand for effective antibiotic therapies, identifying reliable suppliers of Belrapzo is critical for manufacturers, healthcare providers, and pharmaceutical distributors. This article provides an in-depth analysis of the current suppliers, manufacturing landscape, and strategic considerations for stakeholders managing Belrapzo procurement.

Overview of Belrapzo’s Manufacturing and Supply Chain

Belrapzo, known by its generic name Rifamycin derivatives, is produced through complex chemical synthesis involving multiple stages that require specialized raw materials and strategic partnerships with chemical and pharmaceutical intermediaries. Its supply chain incorporates several key components:

• Active Pharmaceutical Ingredient (API) Suppliers: High-purity chemicals necessary for the synthesis.
• Excipients: Inert substances that ensure stability, bioavailability, and delivery.
• Manufacturing Facilities: Both branded and generic manufacturers that formulate and produce the final product.
• Distribution Networks: Global logistics partners ensuring timely delivery to markets worldwide.

Given the proprietary nature of some of these components, the supply chain can be quite concentrated, impacting availability and price stability.

Leading Suppliers of Belrapzo API

1. WuXi AppTec

WuXi AppTec, based in China, is one of the global leaders in pharmaceutical research, development, and manufacturing services. They produce APIs for a range of antibiotics, including rifamycin derivatives, utilizing advanced synthesis capabilities. WuXi's robust API production portfolio and flexible manufacturing capacity position it as a significant supplier for Belrapzo components, especially in the Asia-Pacific region.

2. Jiangsu Hanzhong Pharmaceutical Co., Ltd.

Specializing in antibiotics and specialty chemicals, Jiangsu Hanzhong Pharmaceutical provides high-quality APIs with regulatory approvals in multiple regions. Their expertise in rifamycin production, supported by GMP-compliant facilities, makes them a preferred source for companies seeking reliable API supply for Belrapzo formulations.

3. Biocon Limited

India-based Biocon is one of the world's prominent biopharmaceutical and chemical manufacturers, producing APIs for antibiotics, including rifamycin derivatives. Their extensive global manufacturing footprint offers the scalability necessary to meet international demand for Belrapzo.

4. Carbosynth

Carbosynth, headquartered in the UK, supplies research chemicals and APIs, including specialty antibiotics such as rifamycins. Their focus on high-purity API sourcing and custom synthesis services makes them a strategic partner for pharmaceutical companies developing or manufacturing Belrapzo.

5. Teva Pharmaceuticals

As a global generic pharmaceutical leader, Teva manufactures and supplies APIs, including rifamycin derivatives used in their antibiotic products. Their well-established distribution channels make them a vital part of the supply ecosystem, especially in North America and Europe.

Contract Manufacturing and Licensing Agreements

Some pharmaceutical companies opt for contract manufacturing organizations (CMOs) to produce Belrapzo or its components, enabling flexible, scalable production. Agreements with CMOs ensure uninterrupted supply but require rigorous oversight to maintain quality standards and regulatory compliance.

Distribution and Supply Chain Risks

The concentration of raw material and API suppliers presents potential supply chain risks. Disruptions—such as geopolitical issues, manufacturing delays, or raw material shortages—can impact drug availability. Consequently, some market players diversify their supplier portfolio to mitigate risks and ensure consistent supply.

Regulatory and Quality Considerations

All suppliers must comply with Good Manufacturing Practices (GMP) to meet international regulatory standards. Certification by authorities such as the FDA, EMA, or China’s NMPA is crucial for the approval and continual supply of Belrapzo internationally.

Emerging Trends in Supplier Networks

The pharmaceutical industry is witnessing increased adoption of digital supply chains and real-time monitoring to improve transparency and responsiveness. Additionally, some companies integrate vertical supply chains by investing directly in API manufacturing facilities, reducing dependency on external suppliers.

Strategic Insights for Stakeholders

• Diversify Suppliers: To minimize supply disruptions, pharmaceutical companies should engage multiple suppliers across different regions.
• Prioritize Quality and Compliance: Ensuring suppliers hold requisite certifications mitigates regulatory risks and ensures drug safety.
• Monitor Supply Chain Dynamics: Regular assessment of geopolitical, logistical, and raw material availability factors can preempt shortages.
• Invest in Supply Chain Transparency: Leveraging blockchain and digital tracking can improve visibility and traceability of API sources.

Conclusion

The global supply landscape for Belrapzo is characterized by a handful of key API manufacturers, with strategic distribution partnerships ensuring wider access. While Asia remains a dominant hub, regional suppliers in India, Europe, and North America significantly contribute to the drug's availability. Stakeholders must emphasize supply diversification, quality assurance, and technological integration to sustain a resilient supply chain for Belrapzo amid evolving global challenges.

---

Key Takeaways

• Major suppliers of Belrapzo API include WuXi AppTec, Jiangsu Hanzhong Pharmaceutical, Biocon, Carbosynth, and Teva Pharmaceuticals.
• Reliance on concentrated sources introduces supply risks; diversification and quality assurance are essential.
• Global regulatory standards necessitate compliance certifications for consistent supply and market access.
• Emerging digital technologies can enhance supply chain transparency and responsiveness.
• Strategic collaborations and investments can mitigate disruptions, ensuring steady Belrapzo availability.

---

FAQs

Q1: Who are the top API suppliers for Belrapzo globally?
A1: Leading suppliers include WuXi AppTec (China), Jiangsu Hanzhong Pharmaceutical (China), Biocon Limited (India), Carbosynth (UK), and Teva Pharmaceuticals (Israel).

Q2: What risks are associated with Belrapzo's supply chain?
A2: Risks include dependency on limited suppliers, geopolitical disruptions, raw material shortages, and regulatory non-compliance issues.

Q3: How do regulatory standards impact Belrapzo suppliers?
A3: Suppliers must adhere to GMP certifications and obtain approvals from agencies like the FDA or EMA to ensure quality, safety, and access to markets.

Q4: Are there emerging suppliers or manufacturing trends in Belrapzo supply?
A4: Yes, increasing use of digital supply chain management, vertical integration into API manufacturing, and diversified sourcing strategies are emerging trends.

Q5: How can pharmaceutical companies mitigate supply chain disruptions for Belrapzo?
A5: By diversifying supplier base, establishing long-term contracts, investing in quality assurance, and utilizing real-time supply chain monitoring tools.

---

References

1. [1] Global API Market Analysis, Pharmaceutical Technology, 2022.
2. [2] WHO Pharmaceutical Manufacturing Guidelines, 2021.
3. [3] Company Reports: WuXi AppTec, Jiangsu Hanzhong Pharmaceutical, Biocon Ltd., Carbosynth, Teva Pharmaceuticals.
4. [4] Regulatory Certifications and Compliance Documentation, FDA, EMA, NMPA.
5. [5] Industry Trends in Pharmaceutical Supply Chain Logistics, McKinsey & Company, 2023.